VIDEO: HER3-DXd shows activity in EGFR-resistant, EGFRm NSCLC

ByPasi A. Jänne, MD, PhD

ByMarley V. Ghizzone

In this video, Pasi A. Jänne, MD, PhD, spoke with Healio about safety and efficacy data from a phase 1 trial of patritumab deruxtecan, HER3-DXd, he presented at the virtual ASCO Annual Meeting.

According to Jänne, director of the Lowe Center for Thoracic Oncology, Belfer Center for Applied Cancer Science and Chen-Huang Center for EGFR Mutant Lung Cancers, and senior physician and professor of medicine at Harvard Medical School, HER3-DXd demonstrated antitumor activity in patients with EGFR inhibitor-resistant, EGFR-mutated non-small cell lung cancer.

“When we looked at the patients that responded it wasn't restricted to any particular EGFR-inhibitor resistance mechanism,” he explained.

Published by:

Sources/Disclosures

Collapse

Source:

Healio Interview; Janne P, et al. Abstract 9007. Presented at: ASCO Annual Meeting (virtual meeting); June 4-8, 2021.

Disclosures: Disclosure: Janne reports receiving stock and other ownership interests from Gatekeeper Pharmaceuticals and Loxo Oncology; serving in a consulting or advisory role for Araxes Pharma, AstraZeneca, Bayer, Biocartis, Biocartis, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, Eisai, Ignyta, Lilly, LOXO, Merrimack, Mirati Therapeutics, Novartis, Nuvalent, Inc., Pfizer, Roche/Genentech, Sanofi, SFJ Pharmaceuticals Group, Silicon Therapeutics, Takeda and Voronoi; and receiving research funding from Astellas Pharma, AstraZeneca, Boehringer Ingelhei, Daiichi Sankyo, Lilly, Puma Biotechnology, Revolution Medicines and Takeda.

Discoveries in Lung Cancer

Read more

VIDEO: HER3-DXd shows activity in EGFR-resistant, EGFRm NSCLC

Related Content